A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease

被引:0
|
作者
Rugeri, Lucia [1 ]
Thomas, Will
Schirner, Kathrin
Heyder, Lisa
Auerswald, Guenter
机构
[1] Hop Cardiol, Unite Hemostase Clin, Hosp Civils Lyon, Lyon, France
关键词
blood products; factor VIII; systematic review; von Willebrand disease; von Willebrand factor; WFH; 2021; GUIDELINES; INHIBITOR DEVELOPMENT; VENOUS THROMBOSIS; CLINICAL-EFFICACY; MANAGEMENT; BIOSTATE(R); DIAGNOSIS; PHARMACOKINETICS; POPULATION; PREVENTION;
D O I
10.1055/a-2253-9701
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background For the treatment of von Willebrand disease (VWD), von Willebrand factor (VWF) concentrates can be used in on-demand, long-term prophylaxis, and surgical prophylaxis regimens. Methods This systematic literature review was conducted to evaluate the efficacy, consumption, and safety of plasma-derived human coagulation FVIII/human VWF (pdVWF/FVIII; Voncento/Biostate) for the treatment of patients with any inherited VWD type. An electronic search was conducted in MEDLINE and Cochrane Library databases on VWD therapies. All retrieved publications were assessed against predefined inclusion/exclusion criteria following the Cochrane group recommendations. Associated pharmacovigilance data were collected across the same time period. Results Eleven publications from eight study cohorts were identified for data retrieval. All were from multicenter studies and included both pediatric and adult patients. Eight publications included evaluations of the efficacy of pdVWF/FVIII for on-demand treatment, eight included long-term prophylactic treatment, and eight included surgical prophylaxis. Treatment protocols and VWF administration methods differed between studies, as did safety evaluations. The clinical response was rated as excellent/good for on-demand treatment in 66 to 100% of nonsurgical bleeds, 89 to 100% in the treatment of breakthrough bleeds during long-term prophylaxis treatment, and hemostatic efficacy in surgical procedures was 75 to 100%. Pharmacovigilance data confirmed a low incidence of adverse events in treated patients. Conclusion This review provides a comprehensive summary of studies that evaluated the use of pdVWF/FVIII in VWD demonstrating the long-term effectiveness and safety of this pdVWF/FVIII across all ages, types of VWD, and treatment settings.
引用
收藏
页码:828 / 841
页数:14
相关论文
共 50 条
  • [1] Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease
    Sidonio, Robert F., Jr.
    Boban, Ana
    Dubey, Leonid
    Inati, Adlette
    Kiss, Csongor
    Lissitchkov, Toshko
    Novik, Dzmitry
    Peteva, Elina
    Taher, Ali T.
    Timofeeva, Margarita Arkadevna
    Vilchevska, Kateryna V.
    Vdovin, Vladimir
    Werner, Sylvia
    Knaub, Sigurd
    Khayat, Claudia
    [J]. BLOOD, 2022, 140 : 8438 - 8439
  • [2] A Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2010, 52 (1340): : 46 - 47
  • [3] Hemostatic management of von Willebrand disease during childbirth with a plasma-derived von Willebrand factor/ factor VIII concentrate
    Iorio, Alfonso
    James, Paula
    Ma, Alice
    Srivastava, Alok
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (10) : 2739 - 2744
  • [4] The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease
    Federici, Augusto B.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2009, 8 (02) : 203 - 210
  • [5] Recombinant Von Willebrand factor concentrate in 2A Von Willebrand disease: comparison to plasma-derived Von Willebrand factor concentrate therapy
    Rajpurkar, Madhvi
    Frey, Mary Jane
    Sabo, Cynthia
    Hollon, Wendy
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2019, 30 (04) : 168 - 170
  • [6] Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease
    Boban, Ana
    Robert, Sidonio F., Jr.
    Dubey, Leonid
    Vilchevska, Kateryna V.
    Inati, Adlette
    Khayat, Claudia Djambas
    [J]. BLOOD, 2023, 142
  • [7] Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease
    Kiss, Csongor
    Boda, Zoltan
    Khayat, Claudia Djambas
    Dubey, Leonid
    Robert, Sidonio F., Jr.
    [J]. BLOOD, 2023, 142
  • [8] Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate
    Vilchevska, Kateryna V.
    Vdovin, Vladimir
    Timofeeva, Margarita
    Khayat, Claudia Djambas
    Inati, Adlette
    Robert, Sidonio F., Jr.
    [J]. BLOOD, 2023, 142
  • [9] Regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate is effective for reducing nosebleeds in children and adults with von Willebrand disease
    Boban, A.
    Sidonio, R. F., Jr.
    Dubey, L.
    Vilchevska, K.
    Inati, A.
    Khayat, C. D.
    [J]. HAEMOPHILIA, 2024, 30 : 20 - 20
  • [10] REAL-WORLD EFFICACY AND SAFETY OF PLASMA-DERIVED VON WILLEBRAND FACTOR-CONTAINING FACTOR VIII CONCENTRATES IN PATIENTS WITH VON WILLEBRAND DISEASE IN ITALY
    Federici, A. B.
    Mairal, E.
    [J]. HAEMOPHILIA, 2023, 29 : 145 - 146